clinical trial · NCT05768035
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Hematological MalignanciesAllogeneic T cell progenitors, cultured ex-vivo
brief summary
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitors (HTLP)) injection to accelerate immune reconstitution after haploidentical hematopoietic stem cell transplantation (HSCT) with post-transplant cyclophosphamide (PT-Cy) in adult patients with hematological malignancies.
started
Jun 6, 2023
primary completion
Jul 1, 2025
completion
Jul 1, 2026
last updated
Sep 25, 2023
official title
An Open-label, Multi-center Phase I/II Study to Assess the Safety and the Efficacy of SMART101 After Haploidentical Peripheral Blood Stem Transplantation With Post-transplant Cyclophosphamide in Subjects With Hematological Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol